NCT05072028View on ClinicalTrials.gov

Mass Balance and Biotransformation Study of [14C]DBPR108 in Human

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

November 28, 2021

Study Completion Date

November 28, 2021

Conditions
Healthy Male Subjects
Interventions
DRUG

[14C]DBPR108

\[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral

Trial Locations (1)

Unknown

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human | Biotech Hunter | Biotech Hunter